Oxford BioDynamics
£9m raise gives management time to enact strategyOxford BioDynamics
H126: encouraging progress but challenges remainOxford BioDynamics
FY25 results: delivering despite the challengesOxford BioDynamics
£7m fundraise secures near-term futureOxford BioDynamics
New EpiSwitch test for Chronic Fatigue SyndromeOxford BioDynamics
PROWES: CiRT utility in guiding treatment decisionsOxford BioDynamics
H125: working towards delivering on objectivesOxford BioDynamics
Seeking deals to enhance EpiSwitch revenue potentialOxford BioDynamics
Fundraise of £7m provides much needed cashOxford BioDynamics
Commercialising cutting edge diagnostics